skip to Main Content
Eap

Letter to NHS England re. criteria for Expanded Access Programme

On 23 August 2017, TreatSMA along with SMA Trust, SMA Support UK and MD UK signed a letter addressed to the Head of Specialised Commissioning Team at NHS England. We urged a review of the published commissioning policy for inclusion of SMA 1 patients in the Expanded Access Programme of nusinersen.

The letter expressed our objection that the EAP should be limited only to babies younger than 7 months and only those with two copies of the SMN2 gene. We believe that these limitations are unfounded and wrong.

Read the letter

Back To Top